Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Purpose Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge is currently unknown. We assessed addition of panitumumab to FOLFIRI (P-FOLFIRI) beyond progression to P-FOLFOX in patients with no RA...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical & translational oncology 2022-11, Vol.24 (11), p.2155-2165
Hauptverfasser:	Aparicio, Jorge, Virgili Manrique, Anna C., Capdevila, Jaume, Muñoz Boza, Félix, Galván, Patricia, Richart, Paula, Oliveres, Helena, Páez, David, Hernando, Jorge, Serrano, Sara, Vera, Ruth, Hernandez-Yagüe, Xavier, Gallego, Rafael Álvarez, Riesco-Martinez, M. Carmen, García de Albeniz, Xavier, Maurel, Joan
Format:	Artikel
Sprache:	eng
Schlagworte:	Medicine Medicine & Public Health Oncology Research Article
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!